1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ)

XVIVO.ST
Xvivo Perfusion AB (publ)SE flagStockholm Stock Exchange
213.60
SEK
-10.00
- -
6.73BMarket Cap
Xvivo Perfusion AB (publ)
XVIVO.ST
(Stockholm Stock Exchange)

Recent

price

213.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
3.52
4.12
5.59
6.12
5.83
7.14
8.33
6.62
8.96
14.07
19.96
26.11
25.78
26.13
Revenue per Share
-0.04
0.41
0.25
0.24
0.07
0.25
0.48
0.19
-1.61
0.28
0.62
3.07
5.47
0.8
3.54
Basic EPS, GAAP
-0.07
0.04
-0.95
-0.22
-0.35
-0.5
-1.18
-2.04
-2.83
-3.68
-3.49
-3.26
-2.6
-4.82
2.49
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.54
4.94
8.29
8.59
13.4
19.26
20.47
21.71
35.11
43.58
47.94
61.75
68.47
67.1
66.41
Book Value per Share
0.5
0.38
3.61
4.09
3.92
10.01
9.88
8.99
13.36
12.2
8.44
23.01
23.79
21.05
21.75
Tangible Book Value per Share
20
20
21
22
23
25
26
27
27
29
30
30
31
31
31
Basic Weighted Avg Shares
- -
69
85
120
138
148
188
221
180
258
415
598
822
812
823
Sales/Revenue/Turnover
- -
14.9
9.31
6.76
2.41
4.92
7.18
1.8
-24.57
-7.25
1.07
0.9
10.87
11.34
8.46
Operating Margin (%)
- -
2
4
12
13
15
17
25
30
32
42
76
88
70
- -
Depreciation Expense
-1
8
5
5
2
6
13
5
-44
8
18
92
172
25
111
Net Income, GAAP
653.24
24.86
30.62
30.64
49.85
16
27.51
6.64
- -
- -
17.42
2.86
13.89
34.74
7.11
Effective Tax Rate (%)
- -
11.69
6.16
4.27
1.09
4.22
6.75
2.24
-24.32
3.15
4.44
15.37
20.94
3.1
13.53
Profit Margin (%)
9
7
75
80
68
234
235
207
391
443
333
692
636
569
612
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
3
2
4
21
23
113
103
LT Debt
89
97
178
185
316
504
540
578
1,008
1,285
1,430
1,945
2,157
2,113
2,092
Total Equity
- -
7.48
3.79
3.06
0.66
1.49
1.87
0.66
- -
- -
0.27
0.31
3.68
2.71
3.04
Return on Invested Capital (%)
- -
8.1
3.84
2.86
0.62
1.55
2.45
0.93
- -
- -
1.39
5.44
8.32
1.24
5.24
Return on Capital (%)
- -
8.69
3.79
2.82
0.6
1.53
2.43
0.88
-5.52
0.71
1.36
5.44
8.4
1.18
5.41
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
11
9
8
LT Borrowings
- -
- -
- -
LT Finance Leases
23
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
15,403
8,867
8,908

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
813
726
773
Cash, Cash Equivalents & STI
416
316
323
Accounts Receivable, Net
117
185
181
Inventories
227
226
269
Total Current Liabilities
178
140
161
Payables & Accruals
- -
- -
- -
ST Debt
11
9
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.28%
16.72%
-2.01%
Free Cash Flow
49.13%
19.82%
85.48%
Net Income, GAAP
-28.98%
81.56%
-85.39%
Sales/Revenue/Turnover
23.26%
36.93%
-1.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
186
210
198
228
822
2025
219
178
226
- -
812
2026
241
239
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.72
0.86
2.72
1.16
5.47
2025
-0.39
0.05
1
- -
0.8
2026
1.15
0.52
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ViewRay, Inc. (VRAY)
Antibe Therapeutics Inc. (ATE.TO)
Visiomed Group (VMGBS.PA)
4DMedical Limited (FDMDF)
Talis Biomedical Corporation (TLIS)
CYduct Diagnostics, Inc. (CYDX)
Business
Xvivo Perfusion AB (publ) (XVIVO.ST) develops, manufactures, and markets perfusion technology solutions for organ transplantation and preservation worldwide. The company offers a comprehensive portfolio of products and services, including organ-specific perfusion machines such as the Heart Assist Transport device for heart preservation, the Liver Assist device for liver perfusion, and the Kidney Assist Transport for kidney preservation; preservation solutions like the proprietary VitriSol cryopreservation medium, Steen Solution for lung ex vivo perfusion, and PermaSol for machine perfusion; and associated services encompassing clinical training, regulatory support, and maintenance programs for transplant centers. Xvivo Perfusion operates primarily in the biotechnology and medtech sectors, targeting organ transplant professionals, hospitals, and research institutions across Europe, North America, and Asia-Pacific, with headquarters in Gothenburg, Sweden, where it was founded in 1989 as a spin-off from Chalmers University of Technology. In recent developments, the company expanded its offerings through the launch of next-generation Heart Assist Transport XX in 2024, enhancing transport capabilities for donor hearts with improved normothermic perfusion features; it also secured CE Mark approval for its PermaSol preservation solution in Europe and initiated U.S. FDA clinical trials for the same product in late 2024. Xvivo Perfusion strengthened its market position via a strategic distribution partnership with OrganOx in 2025 for liver perfusion technologies in select regions and completed the acquisition of certain assets from a U.S.-based biopreservation firm in early 2025 to bolster its cryopreservation portfolio. Additionally, the company announced a major funding round in mid-2025, raising SEK 500 million through a rights issue to support global expansion and R&D investments in lung and thoracic organ technologies. These initiatives reflect Xvivo Perfusion's ongoing shift toward integrated, end-to-end organ recovery ecosystems amid growing demand for machine perfusion in solid organ transplantation.